Abstract Imaging, clinical, and pre-clinical studies have provided ample evidence for a cerebellar involvement in cognitive brain function including cognitive brain disorders, such as autism and schizophrenia. We previously reported that cerebellar activity modulates dopamine release in the mouse medial prefrontal cortex (mPFC) via two distinct pathways: (1) cerebellum to mPFC via dopaminergic projections from the ventral tegmental area (VTA) and (2) cerebellum to mPFC via glutamatergic projections from the mediodorsal and ventrolateral thalamus (ThN md and vl). The present study compared functional adaptations of cerebello-cortical circuitry following developmental cerebellar pathology in a mouse model of developmental loss of Purkinje cells (Lurcher) and a mouse model of fragile X syndrome (Fmr1 KO mice). Fixed potential amperometry was used to measure mPFC dopamine release in response to cerebellar electrical stimulation. Mutant mice of both strains showed an attenuation in cerebellar-evoked mPFC dopamine release compared to respective wildtype mice. This was accompanied by a functional reorganization of the VTA and thalamic pathways mediating cerebellar modulation of mPFC dopamine release. Inactivation of the VTA pathway by intra-VTA lidocaine or kynurenate infusions decreased dopamine release by 50 % in wildtype and 20-30 % in mutant mice of both strains. Intra-ThN vl infusions of either drug decreased dopamine release by 15 % in wildtype and 40 % in mutant mice of both strains, while dopamine release remained relatively unchanged following intra-ThN md drug infusions. These results indicate a shift in strength towards the thalamic vl projection, away from the VTA. Thus, cerebellar neuropathologies associated with autism spectrum disorders may cause a reduction in cerebellar modulation of mPFC dopamine release that is related to a reorganization of the mediating neuronal pathways.
Introduction
Autism is a neurodevelopmental disorder characterized by deficits in social skills and communication, unusual and repetitive behavior, and deficits in cognitive function [1] . Neuropsychological testing has revealed that patients with autism also have specific deficits in cognitive function including impairments in memory and attention, executive function, planning, cognitive flexibility, rule acquisition, and abstract thinking [2] . The etiological factors in autism and autism spectrum disorders (ASD) are enigmatic and have been linked to genetic mutations as well as exposure to environmental agents [3] [4] [5] [6] [7] .
Regardless of etiology, cerebellar neuropathology commonly occurs in autistic individuals. Cerebellar hypoplasia and reduced cerebellar Purkinje cell numbers are the most consistent neuropathologies linked to autism [8] [9] [10] [11] [12] [13] . MRI studies report that autistic children have smaller cerebellar vermal volume in comparison to typically developing children [14] . Postmortem studies indicate that in addition to reduced Purkinje cell numbers, microanatomic abnormalities of the cerebellum in this population include excess Bergmann glia, reductions in the size and number of cells in the deep cerebellar nuclei, and an active neuroinflammatory process within cerebellar white matter [15] [16] [17] .
Using a mouse model, we have previously investigated how developmental damage of the cerebellum influences the appearance of autism-like symptoms and cognitive deficits, as well as the neural mechanisms by which this could occur. Lurcher (Lc/+) mutant mice have an autosomal dominant mutation that results in a nearly complete loss of cerebellar Purkinje cells between the second and fourth weeks of life [18, 19] . Since these mice are ataxic, we have used non-ataxic chimeric mice (Lc/+↔+/+), which have a variable loss of Purkinje cells dependent upon the incorporation of the wildtype lineage, to examine the behavioral impact of cerebellar Purkinje cell loss [20] . We found that (1) chimeric mice with reduced numbers of cerebellar Purkinje cells show exaggerated repetitive behaviors [21] . (2) Lurcher mice and chimeras display impaired executive function as measured in a serial reversal learning task [22] . (3) Both repetitive behaviors and executive function errors were significantly, negatively correlated with the number of Purkinje cells obtained from cell counts [21, 22] . (4) Cerebellar output through the dentate nucleus (DN) modulates dopamine release in the medial prefrontal cortex (mPFC) via two independent pathways [23] . Both of these pathways originate in the cerebellar cortex and then project to the deep cerebellar nuclei (see inset in Fig. 3 ). The first involves indirect activation of mesocortical dopaminergic neurons via contralateral glutamatergic projections of the DN to reticulo-tegmental nuclei (RTN) that, in turn, project to pedunculopontine nuclei (PPT) and then project to, and stimulate directly, ventral tegmental area (VTA) dopaminergic cell bodies projecting to the medial mPFC [24] [25] [26] [27] [28] . The second involves activation of the contralateral glutamatergic projections of the DN to thalamic mediodorsal and ventrolateral nuclei (ThN md and ThN vl) that send glutamatergic efferents to the mPFC to modulate mesocortical dopaminergic terminal release in the mPFC via appositional excitatory glutamatergic synapses [29] [30] [31] . (5) Blocking glutamatergic transmission along either of these pathways reduced cerebellar-dependent mPFC dopamine release by around 50 % in each case, suggesting that the two pathways contribute equally and that they are primarily, if not entirely, glutamatergic [32] . Dopamine dysregulation in the mPFC is thus a possible neuronal mechanism underlying the deficits in repetitive behaviors and executive function [22] .
The aim of the present study was to compare adaptations of cerebello-cortical circuitry mediating cerebellar mPFC dopamine modulation following developmental cerebellar pathology relevant to ASD. We used two mutant mouse strains with different forms of cerebellar deficits.
Fragile X syndrome is one of the rare ASD with a known monogenetic cause, here the loss of function of the Fmr1 gene. Fmr1 KO mice have an Fmr1 tm1Cgr targeted mutation and are widely used as a mouse model of fragile X syndrome [33, 34] . Fmr1 KO mice display cerebellar abnormalities such as elongated Purkinje cell spines and decreased volume of deep cerebellar nuclei [35, 36] . Mice from the second mutant strain used here (Lurcher) suffer from developmental loss of all cerebellar Purkinje cells. There is no known human equivalent to this genetic condition. We used fixed potential amperometry to monitor mPFC dopamine release evoked by DN electrical stimulation before and after inactivation of glutamatergic transmission through the ThN md/ThN vl and VTA pathways in urethane anesthetized mice.
Materials and Methods

Animals
Experimental subjects were bred and maintained in the Animal Care Facility located in the Department of Psychology at the University of Memphis. Mice were continuously maintained in a temperature-controlled environment (21±1°C) on a 12:12 light:dark cycle (lights on at 0800 hours) and were given free access to food and water. [24] ), a concentric bipolar stimulating electrode (CBARD75, 125 μm outer and 25 μm inner pole diameter, FHC, ME), and a 31-g stainless-steel guide cannula for drug microinfusions into appropriate nuclei. The Ag/AgCl reference/auxiliary combination electrode was placed at the surface of the cortex and contralateral to the recording electrode which was placed in mPFC of the left hemisphere at a 30°lateral to medial angle (coordinates from bregma: AP +2.35 mm, ML + 1.0 mm, DV −1.5 mm from dura [37] ). The stimulating electrode was placed in the right DN (coordinates from bregma: AP −6.24 mm, ML −2.1 mm, DV −2.25 mm from dura [37] ). Due to differences in cerebellum size from the developmental loss of Purkinje cells and based on histological analysis, the stimulating electrode [23] coordinates for the right DN in Lurcher mutant mice corresponded to the following: from bregma, AP −5.85 mm, ML −1.0 mm, DV −1.0 mm from dura). The guide cannula tip was placed 1 mm above in the VTA, ThN md, or ThN vl (coordinates from bregma: AP −3.3 mm, ML +0.35 mm, DV −3.0 mm from dura; AP −1.35 mm, ML +0.4 mm, DV −2.75 mm from dura; AP −1.35 mm, ML +1.0 mm, DV −3.45 mm from dura, respectively [37] ).
Fixed Potential Amperometry and Electrical Stimulations
After implantation of all electrodes and cannulae, a constant voltage of +0.8 V was applied to the recording electrode and oxidation current (corresponding to changes in extracellular dopamine concentrations) sampled continuously (10,000 samples/s) via an electrometer (ED401 e-corder 401 and EA162 Picostat, eDAQ Inc., Colorado Springs, CO, USA) filtered at 10 Hz low pass [24] . Electrical stimulation of the DN consisted of 100 cathodic monophasic pulses (400 μA intensity, 0.5 ms pulse duration) at 50 Hz every 60 s for a period of 10 to 15 min and were applied to the stimulating electrode via an optical isolator and programmable pulse generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel).
Pathway Inactivations
Following approximately 5 min of baseline recording, separate groups of mice received microinfusions of lidocaine (0.02 μg), kynurenate (0.5 μg), or 10 mM phosphatebuffered saline (PBS). Infusions were administered via the guide cannula. Drugs were first back-loaded into a fiberglass infusion cannula (80 μm o.d., Polymicro Tech. Inc., Phoenix, AZ, USA) and then connected via PE10 tubing to a 1.0-μl microsyringe (Scientific Glass Engineering, Inc., Austin, TX, USA). The infusion cannula was then placed into the guide cannula to extend 1 mm from its tip into the injection site. A 0.5-μl infusion of lidocaine, kynurenate, or PBS was then administered over a 1.0-min period and left in place for an additional minute. Changes in DN stimulationevoked dopamine oxidation current in the mPFC were then recorded for 10 min post-infusion.
Data Analyses
The three DN stimulation-evoked responses immediately prior to each drug infusion as well as the three responses following infusion were extracted from the continuous record, and amperometric currents within the range of 0.2 s pre-stimulation and 60 s post-stimulation were normalized to zero current values. The currents for each evoked response were then summed across time (−0.2 through 60 s) for each response due to dopamine concentrations significantly differing from pre-stimulation baseline for several seconds post-stimulation [23, 32] . As the pre-infusion responses and the post-infusion responses were each 1 min apart, two repeated measures analyses of variance (ANOVA) were conducted for each mouse genotype with time (1-3) of each pre-infusion response or time (1-3) of each post-infusion response, as a within-groups factor. For all analyses, site of infusion and drug administered were between-group factors, and the response sums at each time point were the dependent variable. These analyses indicated that the stimulation-evoked responses did not differ significantly across either pre-infusion times (1-3) or postinfusion times (1-3; p > .05). Because the stimulationevoked responses did not vary significantly, we averaged the three pre-and post-infusion response current sum values to determine pre-with post-infusion responses, respectively. Effects of infusion for each mouse were expressed as average post-infusion changes relative to pre-infusion baseline responses. Using average post-infusion percent decrease as the dependent variable, the general data analytic strategy was analysis of variance (ANOVA). Depending on the ANOVA, strain (Lurcher or Fmr1), genotype (wildtype or mutant), site (VTA, ThN md, or ThN vl), and drug (PBS, lidocaine, or kynurenate) were used as the between-subjects factors. Interactions were investigated with either Sidak-Bonferroni post-hoc comparisons or simple main effects tests.
Histology
Immediately following each experiment, a direct current (100 μA for 10 s; +5 V for 5 s) was passed through the stimulating electrode in the DN to leave iron deposits and through the recording electrode in the mPFC to lesion tissue, respectively. Each mouse was then euthanized with a lethal intracardial injection of urethane. The brains were removed and preserved overnight in 10 % buffered formalin containing 0.1 % potassium ferricyanide, and then stored in 30 % sucrose/10 % formalin solution until sectioning. At the conclusion of the experiment, the brains were sectioned on a cryostat at −30°C. A Prussian blue spot indicative of the redox reaction of ferricyanide and iron deposits labeled the stimulating electrode tip in the DN, while placements of the recording electrodes in the mPFC were determined by the position of the electrolytic lesion, and placements of cannulas were determined by the position of the drug infusion guide cannula. Placements of the electrodes and cannulae were confirmed under light microscopy and recorded on representative coronal diagrams [37] . Figure 1 depicts the central placements of stimulating and recording electrodes and infusion cannula tips in each mouse genotype. In Lurcher mutants (n=54), the stimulating electrode tip locations were confined within the DN ranging from, in millimeters, −5.4 to −6.2 AP, +0.7 to +1.3 ML, and −0.7 to −1.4 DV. In all other groups, the stimulating electrode tip locations were confined within the DN (n=135 electrodes; ranging from, in millimeters, −6.0 to −6.5 AP, +1.7 to +2.7 ML, and −2.1 to −3.25 DV) posterior to bregma, lateral to midline, and ventral from dura. Infusion cannula tips were confined to the ThN md (n=63; ranging from, in millimeters, −1.05 to −1.45 AP, +0.15 to +0.7 ML, and −2.4 to −3.5 DV), the ThN vl (n=63; ranging from, in millimeters, −1.2 to −1.45 AP, +0.6 to +1.3 ML, and −3.1 to −3.95 DV), and the VTA (n=63; ranging from, in millimeters, −3.1 to −3.3 AP, +0.15 to +0.55 ML, and −3.6 to −4.5 DV) posterior to bregma, lateral to midline, and ventral from dura. Recording electrode surface locations were confined within the mPFC (n=189; ranging from, in millimeters, +2.2 to + 2.6 AP, +0.1 to +0.6 ML, and −0.8 to −1.55 DV) anterior to bregma, lateral to midline, and ventral from dura.
Results
Stereotaxic Placements of Electrodes and Drug Infusion Cannulae
Drug Pre-Infusion DN Stimulation-Evoked Dopamine Release Figure 2 shows representative mPFC dopamine release evoked by DN stimulation, immediately prior to drug infusion. Regardless of mouse strain or genotype, electrical stimulation (100 pulses at 50 Hz) of the DN evoked a significant increase in mPFC dopamine release (change in oxidation current) that peaked within 5 s after stimulation and then declined gradually towards baseline pre-stimulation levels over the course of approximately 1 min. The time course of DN stimulation-evoked mPFC dopamine release was similar in both mutant and wildtype mice of both strains. However, mutants of both strains showed a marked and consistent attenuation in the magnitude of evoked dopamine release compared to their wildtype littermates.
Effects of Drug Infusions on DN Stimulation-Evoked Dopamine Release in mPFC
An initial ANOVA used strain (Lurcher or Fmr1), genotype (wildtype or mutant), site of infusion (VTA, ThN md, or ThN vl), and drug (PBS, lidocaine, or kynurenate) as factors. This analysis indicated that mouse strain interacted significantly with genotype and site of infusion (F(2,153)=4.5, p=.01), and that mouse genotype interacted significantly with site and drug (F(4,153)=32.22, p<.001). Thus, subsequent ANOVAs were used to compare wildtype and mutant animals within either the Lurcher or Fmr1 strains. These ANOVAs again indicated that wildtype and mutant mice within each strain differed significantly as a function of drug and site of infusion (Lurcher: F(4,81)=10.20, p<.001; Fmr1: F(4,72)=38.76, p<.001). Therefore, a third series of four ANOVAs was conducted on each genotype (Lurcher wildtype, Lurcher mutant, Fmr1 wildtype, and Fmr1 mutant mice). Table 1 shows the infusion site-specific percent decreases following PBS, lidocaine, or kynurenate in each mouse strain. Both lidocaine and kynurenate infusions at each of the injection sites achieved their maximal inhibitory effects on DN stimulation-evoked dopamine release in the mPFC within 1 min of infusion. ANOVAs indicated a significant interaction between drug and site of infusion for each mouse genotype (Lurcher wildtype mice: F(4,36)=467.51, p=.001; Lurcher mutant mice: F(4,45)=4.261, p=.005; Fmr1 wildtype mice: F(4,36)=34.78, p<.001; and Fmr1 mutant mice: F(4,36)= 12.79, p<.001). Sidak-Bonferroni post-hoc comparisons indicated that the average percent decrease in DN stimulationevoked mPFC dopamine release in all groups receiving PBS was significantly different from that of the associated groups receiving either lidocaine or kynurenate (p<.008). Additionally, the average percent decrease in DN stimulation-evoked mPFC dopamine release of each group receiving lidocaine did not differ significantly from that of the groups of the same mouse genotype which received kynurenate (p>.05).
As the average percent decrease of DN stimulationevoked mPFC dopamine release was similar following either lidocaine or kynurenate, simple main effects tests were conducted on the kynurenate results in order to determine significant differences between wildtype and mutant animals following drug infusion into VTA, ThN md, or ThN vl. By comparing kynurenate-induced attenuation in wildtype and mutant mice within the same strain, it was possible to determine the relative contributions of pathways through the VTA, ThN md, or ThN vl to total DN stimulation-evoked mPFC dopamine release. As shown in Fig. 3 , dopamine release declined by ∼50 % following VTA infusion of kynurenate in Lurcher wildtype mice, which indicated that this pathway accounted for 50 % of the total DN stimulation-evoked mPFC dopamine release. In contrast, there was an attenuation of only ∼30 % in Lurcher mutants, indicating a 20 % reduction in dopamine modulatory strength in the pathway through the VTA. This difference between Lurcher wildtype and mutant mice was significant (F(1,9)=10.86, p=.009). Very similar results were obtained in Fmr1 wildtype (∼50 % decrease) and mutant (∼20 % decrease) mice following infusion of kynurenate into the VTA (F(1,8)=279 .38, p<.001).
Kynurenate-induced reductions in DN stimulationevoked mPFC dopamine release following infusions into the ThN md ranged between ∼30 % and 40 % in wildtype and mutant mice of both strains. Wildtype and mutant mice of the Lurcher (F(1,9) =1.47, p=ns) or Fmr1 (F(1, 8)=1 .86, p=ns) strains did not differ significantly in the response to intra-ThN md kynurenate infusions.
Following kynurenate infusion into the ThN vl, DN stimulation-evoked mPFC dopamine release was reduced by ∼15 % in both Lurcher and Fmr1 wildtype mice. In marked contrast, evoked mPFC dopamine release in Lurcher and Fmr1 mutant mice decreased by ∼40 %. In both strains, the mutant and wildtype mice differed significantly following kynurenate infusion into the ThN vl (Lurcher: F(1,9)=61.02, p<.001; Fmr1: F(1,8)=313.70, p<.001). Considered together with the effects of kynurenate in the VTA, these results indicate that the Lc/+ and Fmr1 mutations were associated with a decrease in dopamine Fig. 1 Representative coronal sections in Lurcher and Fmr1 wildtype and mutant mice illustrating placements (gray shaded areas) of (A) stimulating electrodes in the dentate nucleus (DN), (B) dopamine recording electrodes in the medial prefrontal cortex (mPFC), (C) infusion cannulae in mediodorsal thalamus (ThN md) and ventrolateral thalamus (ThN vl), and (D) infusion cannulae in the ventral tegmental area (VTA). Numbers correspond to millimeter from bregma. Placements of stimulating and recording electrodes, and cannula placements overlapped in all groups. Sections were adapted from the mouse atlas of [37] modulatory strength in the DN→ RTN → PPT →VTA→ mPFC pathway along with a compensatory increase in strength in the DN→ThN vl→mPFC pathway. Dopamine modulation strength through the ThN md pathway was similar regardless of strain or genotype. It should be noted that within each mouse genotype, the sum of the percent decreases for both pathways accounted for 100 % of stimulation-evoked dopamine release recorded in the mPFC. It is thus unlikely that a third alternative pathway exists that was not investigated here.
Discussion
Developmental neuropathology of the cerebellum is a common occurrence in autism and ASD. The current study aimed to compare changes in cerebello-cortical circuitry mediating cerebellar modulation of mPFC dopamine in two strains of mutant mice with cerebellar neuropathology associated with ASD. Our results confirm previous findings of two separate, glutamatergic pathways: the VTA (DN→ RTN→PPT→VTA→mPFC) and the thalamic (DN→ThN md/vl → mPFC) pathway for cerebellar modulation of mPFC dopamine [23, 32] . The average percent decrease in DN stimulation-evoked mPFC dopamine release following infusion of the sodium channel blocker lidocaine or the broad-spectrum glutamate receptor antagonist kynurenate into the VTA, ThN md, or ThN vl did not significantly differ, confirming that both pathways are primarily glutamatergic.
Additionally, because mPFC dopamine release reductions following inactivation of the thalamic and VTA pathways summed to ∼100 %, cerebellar modulation of mPFC dopamine appears to be completely accounted for by these two pathways.
Here, we show that cerebellar neuropathology is associated with weakening of cerebellar modulation of mPFC dopamine transmission (see Fig. 2 ) and with a functional reorganization of the balance between the two pathways (see Fig. 3 ). In wildtype mice of both strains, cerebellar modulation of mPFC dopamine was mediated equally by the VTA and thalamic pathways. However, in both the Lurcher mutant and Fmr1 mutants, there was a shift in modulatory control away from the VTA towards the thalamic pathway, with a specific increase in modulatory strength on the dopamine signal through the ThN vl.
It seems reasonable that this shift away from the VTA may be the result of a loss of cerebellar output as both Lurcher and Fmr1 mutant mice have been reported to have cerebellar abnormalities that could impair cerebello-cortical connectivity. As noted previously, Lurcher lose nearly all Purkinje cells, which constitute the sole output of the cerebellar cortex [18, 19] , but maintain most of their cerebellar nuclei, the main cerebellar output structure, but with abnormally potentiated GABAergic conductances [38] . Fmr1 mutant mice are reported to have more subtle cerebellar neuropathology including elongated spines on cerebellar Purkinje cells and decreased volume of deep cerebellar nuclei, which may also be indicative of reduced cerebellar Fig. 2 Individual examples of changes in medial prefrontal cortex (mPFC) dopamine oxidation current (corresponding to changes in extracellular dopamine concentrations) in Lurcher and Fmr1 wildtype and mutant mice evoked by electrical stimulation of the cerebellar dentate nucleus (black bar, 100 pulses at 50 Hz) just prior to drug infusion. Mutant mice of both strains consistently showed a marked attenuation in the mPFC dopamine response output [35, 36] . Despite having different cerebellar abnormalities, both the Lurcher and Fmr1 mutant mice display similar adaptations of cerebello-mPFC dopamine modulating circuitry with overall modulatory control weakened and a shift in balance from the VTA to the thalamic circuit. These similarities in adaptation are also noteworthy given the different genetic backgrounds of Lurcher (BL6) and Fmr1 mice (FVB).
We suggest that the observed reorganization of cerebellocortical circuitry as well as the attenuation of modulatory influence may underlie the cognitive deficits previously observed in Lurcher mice and Lurcher WT chimeras, in that both the frequency of stereotyped repetitive behavior and the severity of deficits in executive function were specifically correlated with cerebellar Purkinje cell number [21, 23] . While relationships between cerebellar neuropathology and cognitive deficits in Fmr1 mutants have not been specifically investigated, it remains possible that some cognitive deficits including hyperactivity and increased perseveration could be linked to the observed reorganization of cerebello- Fig. 3 Average percent decrease in dentate nucleus (DN) stimulationevoked dopamine responses following kynurenate infusion into the ventral tegmental area (VTA), mediodorsal thalamus (ThN md), or the ventrolateral thalamus (ThN vl), as well as the summed average percent decrease of each drug infused across sites. In Lurcher and Fmr1 wildtype mice, infusions of kynurenate into the VTA reduced dopamine responses by ∼50 %, while kynurenate infusions into the thalamus (md and vl combined) also reduced the dopamine response by a total of ∼50 % (md=∼35 % and vl=∼15 %). In contrast, the reduction in the dopamine response following kynurenate into the VTA in Lurcher mutant (∼30 %) and Fmr1 mutant (∼20 %) mice was significantly less, indicating a reduction in the modulatory strength of this pathway. This reduction in strength in mutant mice was coupled to an increase in signal strength of the pathway through the thalamus, specifically the ThN vl. Thus, kynurenate infused into this nucleus reduced dopamine responses by ∼15 % in wildtype mice of both strains and ∼40 % in mutant mice of both strains. Regardless of strain or genotype, kynurenate infused into the ThN md reduced the dopamine signal between 30 % and 40 %. The inset figure shows the two independent pathways by which cerebellar output through the DN modulates dopamine release in the mPFC. See text for additional description cortical circuitry as the mPFC plays a role in both deficits [39] [40] [41] [42] . Converging evidence from clinical studies increasingly supports the notion that developmental cerebellar neuropathology is associated with autism and ASD. Our data link cerebellar neuropathology directly to deficits in mPFC dopamine regulation through developmental adaptive changes in cerebello-cortical circuitry. Relevant to ASD, cerebellar abnormalities such as ectopic Purkinje cells, focal cerebellar Purkinje cell loss, and Bergmann gliosis are associated with Fragile X syndrome [43, 44] . Asperger's syndrome has been associated with lower total cerebellar volume and lower gray matter volume in the right cerebellum [45] [46] [47] . According to postmortem studies, patients with Rett syndrome display reduced volume of the cerebellum, cerebellar atrophy, and reduced Purkinje cell number [48, 49] .
Indirect evidence of changes in cerebello-cortical circuitry comes from a variety of sources. Prefrontal cortex and thalamic abnormalities are found in patients with autism, and the degree of abnormality in these areas is correlated with severity of symptoms. Our data suggest that these deficits might, at least in part, be caused by deficiencies in cerebellar output affecting cerebello-cortical pathways. During early brain development, the frontal cortex is larger in individuals with autism, and increased volume of frontal lobe cortex has been shown to be positively correlated with autistic symptoms [50, 51] . Importantly, the degree of enlargement of the frontal cortex is also positively correlated with the degree of hypoplasia in the cerebellum [52] . While total brain volume is positively correlated with the volume of the thalamus in control brains, a lack of correlation exists between total brain volume and volume of the thalamus in autistic brains [53] [54] [55] . The size of the thalamus in autistic patients is reduced when compared to controls, and the size of the left thalamus in children with ASD is inversely correlated with stereotypical and repetitive behaviors [54, 56] .
Thus far, dopamine activity in the mPFC has received little attention in connection with ASD. A single pre-clinical study indicated dopaminergic abnormalities in the mPFC of autistic children. Using positron emission tomography (PET), it was found that autistic children have reduced dopaminergic activity in the mPFC compared to controls [57] . Lower levels of mPFC dopamine activity have been associated with deficits to a variety of cognitive functions including attention, working memory, and planning [58] [59] [60] [61] .
While evidence from patients and from mouse models of autism suggests that the cerebellar pathology associated with autism results in adaptations in cerebello-cortical circuitry and cognitive deficits, it is unclear whether these neuropathologies occur as part of the cascade of events that follow developmental cerebellar damage, or how they contribute to the range of symptom severity commonly observed in autism and ASD. It should be noted that a diverse range of abnormalities in other brain areas have been reported in Lurcher and Fmr1 mutant mice. Lurcher mutant mice display prominent ataxia and are impaired in motor-related learning tasks. Given that the PPT also projects to dopaminergic neurons in the substantia nigra [24] , it is conceivable that nigrostriatal dopaminergic transmission may be disrupted in Lurcher and possibly Fmr1 mutant mice. However, there appear to be no differences in striatal tissue content of dopamine and its metabolites or in the densities of dopamine reuptake sites and D1 and D2 receptors in Lurcher mutant and wildtype mice [62] [63] [64] . Regardless, autism patients also display neuropathologies in multiple brain areas in addition to the cerebellum. While the striking similarities observed in the adaptation of cerebello-mPFC dopamine-mediating circuitry in the two mouse models support the notion that they are due to shared cerebellar deficits, additional studies involving exclusive cerebellar pathology are required to confirm our notion (e.g., conditional KOs directed specifically to Purkinje or granule cells).
Conclusions
We have previously shown that the cerebellum modulates mPFC dopamine release via two distinct glutamatergic pathways [23, 32] . Here, we show that developmental cerebellar pathology associated with ASD causes a reorganization of cerebello-cortical circuitry which results in attenuated modulation of mPFC dopamine transmission and a shifting of balance between the two pathways. Our results suggest that these functional modifications in cerebello-cortical connectivity may be a common consequence of developmental damage to the cerebellum with potential relevance to cerebellar cognitive function in general.
